Stay updated on LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Sign up to get notified when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.

Latest updates to the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page
- Check4 days agoChange DetectedVersion bump from v3.0.1 to v3.0.2 and removal of the Back to Top control; overall, a minor update with no substantive changes to core content.SummaryDifference0.2%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.2%
- Check18 days agoChange DetectedThe web page has been updated to include new drug information and facility details, while several previous drug entries and location terms have been removed, indicating a shift in focus towards specific treatments and facilities.SummaryDifference7%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check47 days agoChange DetectedThe page has been updated to version v2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference1%
Stay in the know with updates to LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.